Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MASP2 | O00187 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
| ▸ | FABP6 | P51161 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 4/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30218684 | 1.00 | MASP2 (0.48) | MASP2MEN1ALDH1A1NUDT1KMT2A | |
| SCHEMBL28811431 | 0.88 | ALDH1A1 (0.47) | MASP2MEN1ALDH1A1NUDT1KMT2A | |
| SCHEMBL30672494 | 0.86 | NPBWR1 (0.58) | BACE1PLAUHTR3EHTR3BHTR3A | |
| SCHEMBL3589452 | 0.86 | NPBWR1 (0.58) | BACE1PLAUHTR3EHTR3BHTR3A | |
| SCHEMBL119520 | 0.83 | XDH (0.56) | MASP2MEN1ALDH1A1NUDT1KMT2A | |
| SCHEMBL13619366 | 0.82 | FABP6 (0.50) | MASP2MEN1ALDH1A1NUDT1KMT2A | |
| Bromide SCHEMBL2381467 | 0.82 | XDH (0.54) | MASP2MEN1ALDH1A1NUDT1KMT2A | |
| Bromide SCHEMBL117671 | 0.82 | XDH (0.54) | MASP2MEN1ALDH1A1NUDT1KMT2A | |
| SCHEMBL5681855 | 0.80 | NPSR1 (0.59) | ALDH1A1KIF11NPBWR1KDM4EMETAP2 | |
| SCHEMBL666767 | 0.79 | NPBWR1 (0.43) | KIF11NPBWR1KDM4EMETAP2DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4351578-A1 | SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE | Stinginn Inc (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117126578-A | Organosilicon polymer/POSS hybrid antifouling coating grafted with antibacterial molecules and preparation method thereof | 中国科学院海洋研究所 | 2023-11-28 | — | — | CN | disclosed |
| WO-2022245986-A1 | SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE | STINGINN INC (US) | 2022-11-24 | — | — | WO | disclosed |
| US-10005769-B2 | 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors | 4SC AG (DE) | 2018-06-26 | — | — | US | disclosed |
| US-20160137637-A1 | 2,3-DIHYDROBENZOFURAN-5YL COMPOUNDS AS DYRK KINASE INHIBITORS | 4SC DISCOVERY GMBH (DE) | 2016-05-19 | — | — | US | disclosed |
| EP-1653951-B1 | BENZIMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-28 | — | — | EP | disclosed |
| EP-1653951-B1 | BENZIMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-28 | — | — | EP | disclosed |
| WO-2011099832-A2 | NOVEL BENZIMIDAZOLE COMPOUND, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CRYSTALGENOMICS, INC. (KR) | 2011-08-18 | — | — | WO | disclosed |
| US-7691886-B2 | Benzimidazole derivatives as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-7691886-B2 | Benzimidazole derivatives as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20070010560-A1 | angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010560-A1 | angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010560-A1 | angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
| EP-1620413-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004098494-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-4316021-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1982-02-16 | — | — | US | disclosed |
| US-4243813-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
| US-4196125-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4118573-A | ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4018790-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010560-A1 | angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis | BRAF, RAF1, VEGFA | MASP2 2940/4885MEN1 2167/4885ALDH1A1 565/4885 |
| US-10005769-B2 | 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors | DYRK2, DYRK1B, DYRK1A | MASP2 2584/4885MEN1 3869/4885ALDH1A1 2116/4885 |
| US-20160137637-A1 | 2,3-DIHYDROBENZOFURAN-5YL COMPOUNDS AS DYRK KINASE INHIBITORS | DYRK2, DYRK1B, DYRK1A | MASP2 2584/4885MEN1 3869/4885ALDH1A1 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.